Over the past decades, there has been an eruption in understanding treatment strategies of gliomas with the development of clinical immunotherapy, providing exceptional success in employing checkpoint inhibitors and cancer vaccines as treatment options that have given significant momentum to the growth of the GBM market. The pre-existing treatment includes complete resection followed by radiotherapy and pharmacological treatment with chemotherapeutic agents, such as temozolomide – a major type of high-grade glioma.
Avastin (bevacizumab) is approved in the GBM market in adult patients whose cancer has progressed after prior treatment (recurrent or rGBM). In Sep...
